Vir Biotechnology Appoints Aziz Sawaf as New CFO
Vir Biotechnology announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf, previously of Theravance Biopharma and Gilead Sciences, will receive a $520,000 base salary, performance-linked bonuses, and significant stock grants. This move is seen as an effort to strengthen Vir's financial leadership as it advances its cancer immunotherapy and hepatitis delta virus programs.
Vir Biotechnology names Aziz Sawaf as chief financial officer
Vir Biotechnology, Inc. announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective Sunday. Sawaf will oversee the company's finance, IT, and investor relations functions, bringing over 20 years of biopharmaceutical experience. He joins from Theravance Biopharma, Inc., where he served as CFO.
Vir Biotechnology Appoints Aziz Sawaf as EVP and CFO
Vir Biotechnology has appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer. Sawaf brings over 20 years of biopharmaceutical experience from both large and small companies, including Theravance Biopharma and Gilead Sciences. In his new role, he will oversee finance, IT, and investor relations, focusing on disciplined capital allocation and advancing the company's pipeline.
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology, Inc. announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf will oversee finance, IT, and investor relations, bringing over 20 years of biopharmaceutical experience from companies like Theravance Biopharma and Gilead Sciences. The company expects his expertise in financial performance and capital allocation to be valuable as it advances its cancer immunotherapy pipeline and hepatitis delta virus program.
A $150K sign-on bonus, contingent on continued employment, awaits Vir Biotechnology (VIR)'s incoming CFO.
Vir Biotechnology (VIR) has appointed Aziz Sawaf as its new Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf will receive an annual base salary of $520,000, a target annual bonus of 45% of his base salary, and a $150,000 sign-on bonus paid in two installments, contingent on continued employment. He will also be granted options for 150,000 shares and 75,000 restricted stock units, vesting over four years.
Vir Biotechnology names Aziz Sawaf as chief financial officer By Investing.com
Vir Biotechnology, Inc. announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective Sunday. Sawaf brings over 20 years of biopharmaceutical experience from Theravance Biopharma and Gilead Sciences, and will oversee Vir Biotechnology's finance, IT, and investor relations functions. The company, a clinical-stage biopharmaceutical firm, focuses on developing medicines for infectious diseases and cancer.
Raymond James reiterates USD 19.00 target for Vir Biotechnology stock
Raymond James has reiterated a Strong Buy rating and a $19.00 price target for Vir Biotechnology (VIR) stock, following clinical results from Mirum Pharmaceuticals. This target is driven by Vir's hepatitis delta programs and its tobevibart and elebsiran combination, expected to compete with existing treatments. The company recently reported significant revenue growth and a reversal to positive net income in Q2 2026, with key clinical data releases anticipated in Q4 2026 and Q1 2027.
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Sell-side brokerages have given Vir Biotechnology, Inc. (NASDAQ:VIR) a "Moderate Buy" rating, with an average 12-month price target of $21.57, significantly higher than its current share price of $10.65. Institutional investors own a substantial 65.32% of the company, and Vir recently surpassed earnings per share and revenue estimates in its latest quarterly report. However, the company reported a negative net margin and return on equity, and analysts project a negative EPS for the current year.
Vir Biotechnology (NASDAQ:VIR) Nears Key Hepatitis Delta Readout
Vir Biotechnology (NASDAQ:VIR) is nearing a significant data readout for its ECLIPSE program targeting chronic hepatitis delta, with the first study's topline results expected in Q4 and subsequent studies in Q1 next year. The company's financial position is strong, with over one billion dollars in cash, extending its operating runway into H2 2028. Hepatitis delta is a severe form of chronic viral hepatitis with limited treatment options, highlighting the urgent medical need Vir Biotechnology aims to address.
Vir Biotechnology stock falls 3.34 percent after Q2 results
Vir Biotechnology stock fell 3.34 percent to USD 10.72 after reporting strong Q2 2026 revenue of USD 238.9 million, largely due to a USD 240 million Astellas upfront payment. Despite the revenue beat and a shift from a net loss to a net income, the stock declined in after-hours trading. The company's future valuation hinges on upcoming clinical trial data, with analyst Patrick Trucchio maintaining a Buy rating and a USD 20 price target.
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR
Engineers Gate Manager LP significantly reduced its stake in Vir Biotechnology (NASDAQ:VIR) by selling 121,964 shares, though institutional ownership remains high. Despite the sale, analyst sentiment for Vir Biotechnology is generally positive, with a "Moderate Buy" consensus and an average price target significantly above its current trading price. The company also surpassed its recent quarterly earnings and revenue estimates.
Former Vir (NASDAQ: VIR) officer sold $315K in stock, with more share sales planned
A former officer of Vir Biotechnology, Jason V. O'Byrne, has filed a Rule 144 notice indicating planned sales of common stock. The filing details recent sales, including 28,333 shares sold for $315,241.46 on September 9, 2026, and outlines future sales from restricted stock vesting and ESPP purchases between late 2025 and mid-2026. This notice is a regulatory requirement for insiders selling restricted securities.
Behavioral Patterns of VIR and Institutional Flows
This article analyzes Vir Biotechnology Inc. (NYSE: VIR) using AI models, identifying a weak near-term sentiment despite long-term strength. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths and key support and resistance levels for VIR.
WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR
WINTON GROUP Ltd significantly reduced its stake in Vir Biotechnology Inc. (NASDAQ:VIR) by 58.3% in the second quarter, selling over 214,000 shares. Despite this reduction, institutional ownership remains high at 65.32%, with major investors like BlackRock and ARCH Venture Management increasing their positions. Vir Biotechnology reported strong quarterly earnings, beating analyst estimates with an EPS of $0.47 and revenue of $238.95 million, maintaining a "Moderate Buy" consensus rating among analysts.
Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR
Legal & General Group Plc has initiated a new position in Vir Biotechnology, Inc. (NASDAQ:VIR), investing $2.76 million to acquire 270,875 shares, representing approximately 0.16% of the company. Institutional investors now own 65.32% of VIR. Despite a recent earnings beat with EPS of $0.47 against estimates of $0.33 and significant revenue growth, Vir Biotechnology remains unprofitable, with analysts projecting a full-year loss of $1.84 per share, and the stock currently holds a consensus "Moderate Buy" rating.
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages
Vir Biotechnology, Inc. (NASDAQ:VIR) has received a "Moderate Buy" consensus rating from eight brokerage firms, with an average 12-month price target of $21.57. The company recently reported strong quarterly earnings, beating EPS estimates by $0.14 and significantly exceeding revenue expectations with a 19582.5% year-over-year increase. Institutional investors hold a substantial 65.32% of the stock, with several firms increasing their stakes.
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR
Bank of New York Mellon Corp has acquired a new stake of 694,374 shares in Vir Biotechnology, Inc. (NASDAQ:VIR) valued at approximately $7.08 million, representing about 0.41% of the company. Institutional investors collectively own 65.32% of VIR, and analysts have a "Moderate Buy" consensus rating with an average price target of $21.57. Vir Biotechnology recently surpassed quarterly expectations with $0.47 EPS and $238.95 million in revenue.
Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR
Man Group plc has acquired a new position in Vir Biotechnology, Inc. (NASDAQ:VIR), purchasing 150,688 shares valued at approximately $1.54 million. This move positions institutional investors to collectively own 65.32% of Vir’s stock. Despite the company reporting strong quarterly earnings and revenue that beat estimates, it remains unprofitable with a negative net margin.
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Vir Biotechnology, Inc. announced that its President and CEO, Marianne De Backer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. A live webcast of the event will be available on the company's investor relations website. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases and cancer.
Vir Biotechnology stock hits 52-week high at 11.66 USD
Vir Biotechnology Inc. (VIR) has reached a new 52-week high of $11.66, with its stock currently trading at $11.70 and showing an 81% year-to-date return. This surge is attributed to growing investor confidence, the company's strong financial performance including a net income of $80.1 million in Q2 2026, and advancements in its hepatitis D virus treatment programs. H.C. Wainwright has reiterated a Buy rating with a $20.00 price target, anticipating positive clinical trial data in late 2026 and early 2027.
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week High - Should You Buy?
Vir Biotechnology (NASDAQ:VIR) recently hit a new 52-week high of $11.74, closing at $10.94, with institutional investors holding a significant portion of its shares. The company surpassed quarterly earnings expectations, reporting $0.47 EPS against an expected $0.33, and revenues of $238.95 million against a forecast of $135.88 million. Despite this, Vir Biotechnology remains unprofitable with a negative net margin of 638.88%, and analysts have a "Moderate Buy" consensus rating with an average price target of $21.57.
Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR
Corient Private Wealth LP has invested $3.17 million in Vir Biotechnology, Inc. (NASDAQ:VIR) by purchasing 310,548 shares during the second quarter, making it approximately 0.18% of their holdings in the company. Institutional investors collectively own 65.32% of Vir’s stock. The company recently reported strong quarterly earnings, surpassing analyst estimates with revenues of $238.95 million and EPS of $0.47, and analysts currently have a "Moderate Buy" rating with an average price target of $21.57.
Vir Biotechnology (NASDAQ:VIR) Trading 4.8% Higher - Here's What Happened
Vir Biotechnology (NASDAQ:VIR) shares increased by 4.8% to $11.46 on Tuesday, despite trading volume being 88% below average. The company has a "Moderate Buy" consensus rating and an average price target of $21.57 from analysts. This positive movement follows Vir Biotechnology exceeding its quarterly earnings expectations, reporting adjusted EPS of $0.47 and revenue of $238.95 million, significantly above forecasts.
BlackRock Inc. Purchases New Position in Vir Biotechnology, Inc. $VIR
BlackRock Inc. has acquired a significant new position in Vir Biotechnology, Inc., purchasing over 20 million shares valued at approximately $210.7 million, giving it a 12.26% stake. Other institutional investors have also adjusted their holdings, with 65.32% of the stock now owned by institutions. Despite a positive analyst outlook with a "Moderate Buy" rating and strong quarterly earnings that beat estimates, the company remains unprofitable.
Vir Biotechnology unveils decade-long timeline spotlighting research advances and company culture
Vir Biotechnology is celebrating its 10-year anniversary by releasing a timeline showcasing its scientific progress, company achievements, traditions, and employee contributions. The company recently reported over $1.0 billion in cash and advancing CHD and oncology pipelines in its second-quarter financial results. As part of its anniversary, Vir Biotechnology also hosted a Family Day, inviting relatives and friends to learn about its operations.
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR
Algert Global LLC increased its stake in Vir Biotechnology (NASDAQ:VIR) by 64.6% in the second quarter, purchasing an additional 315,969 shares. The firm now holds 804,977 shares valued at $8.2 million. Despite reporting strong quarterly earnings that beat estimates, the company continues to show substantial losses, with a negative net margin of 638.88%.
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR
ADAR1 Capital Management LLC has acquired a new stake of 2,456,677 shares in Vir Biotechnology, Inc. (NASDAQ:VIR) during the second quarter, valued at approximately $25,034,000, making it their 17th largest position. Other institutional investors like BlackRock Inc. and Pictet Asset Management Holding SA have also adjusted their holdings in Vir Biotechnology. Analysts currently rate Vir Biotechnology as a "Moderate Buy" with a consensus target price of $20.62.
ARCH Venture Management LLC Invests $129.35 Billion in Vir Biotechnology, Inc. $VIR
ARCH Venture Management LLC has acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) worth approximately $129.35 billion, making it their 6th largest holding. Other institutional investors have also adjusted their positions in the company. Vir Biotechnology's stock recently traded up 8.1% and the company reported stronger-than-expected earnings for the last quarter.
Vir Biotechnology climbs 9% amid post-earnings uptrend (VIR:NASDAQ)
Shares of Vir Biotechnology (VIR) climbed almost 9% on Tuesday, continuing an upward trend that has seen the stock gain in 11 of the previous 12 sessions. The surge is attributed to stronger-than-expected revenue, a positive swing in net income despite an EPS miss, and upcoming data catalysts from clinical studies. The company's cash and investments exceeding $1 billion have also boosted investor confidence.
Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1% - Time to Buy?
Vir Biotechnology (NASDAQ:VIR) shares rose 8.1% to $10.71, though trading volume was significantly lower than average. Analysts generally rate the stock as a "Moderate Buy" with an average price target of $20.62, nearly double its current price. Despite beating quarterly earnings and revenue estimates, the company remains unprofitable, with institutional investors owning a substantial 65.32% of the stock.
Vir Biotechnology (NASDAQ: VIR) ex-officer lines up more sales
A former officer of Vir Biotechnology (VIR), Jason V. O'Byrne, plans to sell up to 23,148 shares of common stock, valued at approximately $242,591.04, through Fidelity Brokerage Services LLC. This planned sale is linked to a stock option exercise, with the transaction expected around August 25, 2026, on NASDAQ. O'Byrne has made two previous sales in August 2026, totaling 39,352 shares for over $387,000.
Parkman Healthcare Partners LLC Takes Position in Vir Biotechnology, Inc. $VIR
Parkman Healthcare Partners LLC has acquired 475,279 shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the second quarter, valued at approximately $4.84 million. This move is part of broader institutional investment, with hedge funds and institutional investors owning 65.32% of the company. Vir Biotechnology has a "Moderate Buy" consensus rating from analysts, with a target price of $20.62, and recently reported strong quarterly earnings, beating revenue and EPS estimates.
Vir Biotechnology (NASDAQ: VIR) officer plans 14,352-share sale after 25K sale
A former officer of Vir Biotechnology (NASDAQ: VIR), Jason V. O'Byrne, plans to sell up to 14,352 shares of common stock with an aggregate market value of $142,124.00, following a stock option exercise on August 24, 2026. This planned sale comes after O'Byrne previously sold 25,000 shares of Vir common stock in the past three months for $245,297.50. The transaction is being made under Rule 144, which outlines conditions for reselling restricted or insider-held shares.
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale
A former officer of Vir Biotechnology, Inc. (NASDAQ: VIR), Jason V. O'Byrne, has filed a Form 144 notice to potentially sell up to 25,000 shares of common stock, valued at approximately $245,297. The sale is planned for August 21, 2026, through Fidelity Brokerage Services LLC, and is connected to a stock option exercise. This regulatory filing indicates an insider's intention to sell shares previously acquired through stock options.
Vir Biotechnology on Track for Record Winning Streak -- Data Talk
Vir Biotechnology, Inc. (VIR) is experiencing a record nine-day winning streak, with its stock currently trading at $9.84, up 3.69%. This performance marks its highest close since July 10, 2026, and represents a 12.26% increase over the current streak, the longest in its recorded history. The company's stock is also up 63.18% year-to-date and 125.69% from 52 weeks ago.
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability
Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with revenues reaching US$238.95 million and net income of US$80.08 million, replacing a prior net loss. This unexpected financial performance, driven partly by a collaboration with Astellas, alters the investment narrative by easing near-term funding concerns. However, the company still faces risks related to clinical trial outcomes and long-term development costs, which remain crucial factors for its future valuation and stock performance.
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability
Vir Biotechnology (VIR) reported a significant swing to quarterly profitability in Q2 2026, with revenue of US$238.95 million and net income of US$80.08 million, replacing previous losses. This shift is largely attributed to a collaboration with Astellas. While improving short-term funding optics, the company still faces risks related to pivotal trial outcomes and development costs, which could impact its long-term financial profile and fair value.
Vir Biotechnology Stock Price Forecast. Should You Buy VIR?
StockInvest.us rates Vir Biotechnology, Inc. (VIR) as a "Buy Candidate" with a technical score of 3.46, noting a 1.62% price gain on the last trading day and a 5.51% increase over two weeks. The analysis indicates mostly positive signals, including buy signals from short and long-term Moving Averages and a pivot bottom point. The stock is expected to trade within a wide horizontal trend between $8.77 and $10.61 over the next three months, with potential resistance at $9.54 and support at $9.16.
Vir Biotechnology Reports 96-Week Phase 2 Hepatitis Delta Data for Tobevibart and Elebsiran Combination
Vir Biotechnology announced complete 96-week Phase 2 SOLSTICE trial data for its combination therapy of tobevibart and elebsiran for chronic hepatitis delta virus (HDV) infection. The regimen demonstrated sustained virologic suppression in 100% of participants and improvements in liver function biomarkers, with no new safety signals. These results support the potential of multi-targeted functional cure strategies for HDV, which is the most severe form of chronic viral hepatitis.
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology (VIR) reported significant financial improvements in Q2 2026, with $1.01 billion in cash and investments and $238.9 million in revenue, driven by a collaboration with Astellas. The company highlighted strong progress in its hepatitis delta program, with promising clinical trial results for elebsiran and tobevibart, and advanced its oncology pipeline, including the VIR-5500 T-cell engager. VIR projects sufficient capital into the second half of 2028 and anticipates key data readouts for its ECLIPSE studies in late 2026 and early 2027.
Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund
Vir Biotechnology, Inc. director Robert J. More reported internal share transfers totaling 16,000 shares of common stock, executed on August 11, 2026. These transactions involved transferring shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) for no consideration in connection with the vesting of restricted stock unit awards. Following these transfers, More directly holds 40,656 shares and indirectly holds 517,917 shares through APNG 1, while disclaiming beneficial ownership of the indirect holdings except for his pecuniary interest.
Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028
Vir Biotechnology's cash reserves exceeded $1 billion in Q2 2026, extending its operational runway into late 2028, primarily due to a strategic collaboration with Astellas. This deal, involving a $240 million upfront payment and a $75 million equity investment, focuses on VIR-5500 for prostate cancer, with pivotal Phase 3 trials anticipated to begin in 2027. The company also reported significant progress in its chronic hepatitis delta program, with Phase 3 enrollment complete and topline data expected soon.
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages
Vir Biotechnology, Inc. (NASDAQ:VIR) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $20.63, significantly higher than its current price of $8.89. The company recently reported strong quarterly earnings, beating revenue and EPS estimates, despite a negative net margin. Insider activity includes a director selling shares, while institutional investors hold a substantial portion of the company's stock.
Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position
State Street Corporation, through its investment management subsidiaries, has disclosed a beneficial ownership of 9,964,151 shares of Vir Biotechnology, Inc. common stock, which represents 5.9% of the class as of June 30, 2026. The filing indicates that all voting and dispositive authority is held on a shared basis among its affiliated investment advisers. This disclosure was made via a SCHEDULE 13G form, which is used for passive investment reporting.
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders
Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with US$80.08 million in net income and sharply increased revenue of US$238.95 million. Despite this improvement, the company missed analyst expectations for both earnings and sales. The article discusses how this mixed performance, alongside strategic collaborations like the Astellas partnership, shapes Vir Biotechnology's investment outlook, emphasizing clinical execution and commercialization as key catalysts.
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Vir Biotechnology (NASDAQ:VIR) from a "sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with a $20.62 target price. The company recently reported strong quarterly earnings, beating EPS and revenue estimates significantly, with revenue soaring by 19582.5% year-over-year. Institutional investors hold a substantial portion of the company, while insider activity showed a director selling a portion of her shares.
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21, Implies 140% Upside
Analysts have slightly lowered the average 12-month price target for Vir Biotechnology, Inc. (VIR) stock from $21.11 to $21, with individual forecasts ranging from $15 to $30. This updated target suggests a potential upside of approximately 140% based on the August 6 closing price. Despite the target adjustment, the consensus rating from 10 analysts remains a "Buy."
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir Biotechnology reported its second-quarter 2026 financial results, highlighting strong progress in its clinical programs for chronic hepatitis delta (CHD) and solid tumors. Key updates include promising Phase 2 SOLSTICE data for elebsiran and tobevibart in CHD, with Phase 3 ECLIPSE 1 trial data expected in Q4 2026, and the initiation of dose-expansion cohorts for VIR-5500 in prostate cancer following a collaboration with Astellas. The company ended the quarter with over $1 billion in cash, cash equivalents, and investments, with a net income of $80.1 million.
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.33, Implies 134% Upside
The average 12-month price target for Vir Biotechnology, Inc. (VIR) stock has been lowered by analysts from $21.56 to $21.11, with individual forecasts ranging from $16 to $30 per share. This updated target suggests a potential upside of approximately 132% based on the August 5th closing price. Despite the target cut, the consensus rating from 10 analysts remains a "Buy," with no "Hold" or "Sell" recommendations.
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology, Inc. (VIR) reported Q2 earnings of $0.47 per share, significantly missing the Zacks Consensus Estimate of $0.83, though it represents an improvement from a loss of $0.8 per share a year ago. The company also missed revenue estimates, posting $238.95 million against an expectation of $258.38 million. Despite these misses, VIR shares have seen a 52.1% gain year-to-date, outperforming the S&P 500.
